Modeling meropenem treatment, alone and in combination with daptomycin, for KPC-producing Klebsiella pneumoniae strains with unusually low carbapenem MICs

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 8, 2016, Pages 5047-5050

  Gagetti, P ^a,b   Pasteran, F ^b   Martinez, M P ^a   Fatouraei, M ^a   Gu, J ^a   Fernandez, R ^a   Paz, L ^a   Rose, W E ^c   Corso, A ^b   Rosato, A E ^a  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b INSTITUTO NACIONAL DE ENFERMEDADES INFECCIOSAS   (Argentina)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ENZYME; CARBAPENEM; CARBAPENEMASE; DAPTOMYCIN; MEROPENEM; BACTERIAL PROTEIN; BETA LACTAMASE; CARBAPENEM DERIVATIVE; THIENAMYCIN DERIVATIVE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL CELL; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CARBAPENEMASE PRODUCING KLEBSIELLA PNEUMONIAE; CELL KILLING; CONTROLLED STUDY; DRUG DISPOSITION; DRUG POTENTIATION; HALF LIFE TIME; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE INFECTION; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; DRUG EFFECTS; ENZYMOLOGY; GENETICS; KLEBSIELLA PNEUMONIAE; METABOLISM; MICROBIAL SENSITIVITY TEST; STAPHYLOCOCCUS AUREUS;

BACTERIAL PROTEINS; BETA-LACTAMASES; CARBAPENEMS; DAPTOMYCIN; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCUS AUREUS; THIENAMYCINS;

EID: 84979519297     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00168-16     Document Type: Article

References (17)

1. Nordmann P, Dortet L, Poirel L. 2012. Carbapenem resistance in Enterobacteriaceae: here is the storm! Trends Mol Med 18:263-272. http://dx.doi.org/10.1016/j.molmed.2012.03.003.
2. World Health Organization. 2014. Antimicrobial resistance: global report on surveillance 2014. World Health Organization, Geneva, Switzerland. http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748-eng.pdf.
3. Pitout JD, Nordmann P, Poirel L. 2015. Carbapenemase-producing Klebsiella pneumoniae, a key pathogen set for global nosocomial dominance. Antimicrob Agents Chemother 59:5873-5884. http://dx.doi.org/10.1128/AAC.01019-15.
4. Tumbarello M, Trecarichi EM, De Rosa FG, Giannella M, Giacobbe DR, Bassetti M, Losito AR, Bartoletti M, Del BV, Corcione S, Maiuro G, Tedeschi S, Celani L, Cardellino CS, Spanu T, Marchese A, Ambretti S, Cauda R, Viscoli C, Viale P. 2015. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother 70:2133-2143. http://dx.doi.org/10.1093/jac/dkv086.
5. Tumbarello M, Viale P, Bassetti M, De Rosa FG, Spanu T, Viscoli C. 2015. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study-authors' response. J Antimicrob Chemother 70:2922. http://dx.doi.org/10.1093/jac/dkv200.
6. Petrosillo N, Giannella M, Lewis R, Viale P. 2013. Treatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art. Expert Rev Anti Infect Ther 11:159-177. http://dx.doi.org/10.1586/eri.12.162.
7. Veliz O, Pasteran F, Guerriero L, Gomez S, Faccone D, Corso A. 2013. Emergence of ertapenem susceptible (ETP S) KPC-producing Enterobactericeae (KPC-PE) with conflicting susceptibility results by reference and routine methods, abstr D598. Abstr 53rd Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC.
8. Mehta S, Singh C, Plata KB, Chanda PK, Paul A, Riosa S, Rosato RR, Rosato AE. 2012. Beta-lactams increase the antibacterial activity of daptomycin against clinical MRSA strains and prevent selection of DAPresistant derivatives. Antimicrob Agents Chemother 56:6192-6200. http://dx.doi.org/10.1128/AAC.01525-12.
9. Randall CP, Mariner KR, Chopra I, O'Neill AJ. 2013. The target of daptomycin is absent from Escherichia coli and other Gram-negative pathogens. Antimicrob Agents Chemother 57:637-639. http://dx.doi.org/10.1128/AAC.02005-12.
10. Pournaras S, Kristo I, Vrioni G, Ikonomidis A, Poulou A, Petropoulou D, Tsakris A. 2010. Characteristics of meropenem heteroresistance in Klebsiella pneumoniae carbapenemase (KPC)-producing clinical isolates of K. pneumoniae. J Clin Microbiol 48:2601-2604. http://dx.doi.org/10.1128/JCM.02134-09.
11. Nodari CS, Ribeiro VB, Barth AL. 2015. Imipenem heteroresistance: high prevalence among Enterobacteriaceae Klebsiella pneumoniae carbapenemase producers. J Med Microbiol 64:124-126. http://dx.doi.org/10.1099/jmm.0.081869-0.
12. Rose WE, Rybak MJ, Kaatz GW. 2007. Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies. J Antimicrob Chemother 60:334-340. http://dx.doi.org/10.1093/jac/dkm170.
13. Bowker KE, Holt HA, Lewis RJ, Reeves DS, MacGowan AP. 1998. Comparative pharmacodynamics of meropenem using an in-vitro model to simulate once, twice and three times daily dosing in humans. J Antimicrob Chemother 42:461-467. http://dx.doi.org/10.1093/jac/42.4.461.
14. Bowker KE, Noel AR, MacGowan AP. 2008. Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 52:4370-4373. http://dx.doi.org/10.1128/AAC.00922-07.
15. Rose WE, Schulz LT, Andes D, Striker R, Berti AD, Hutson PR, Shukla SK. 2012. Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity. Antimicrob Agents Chemother 56:5296-5302. http://dx.doi.org/10.1128/AAC.00797-12.
16. Blaser J. 1985. In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives. J Antimicrob Chemother 15 (Suppl A):125-130.
17. Fattouh R, Tijet N, McGeer A, Poutanen SM, Melano RG, Patel SN. 2015. What is the appropriate meropenem MIC for screening of carbapenemase-producing Enterobacteriaceae in low prevalence settings? Antimicrob Agents Chemother 60:1556-1559. http://dx.doi.org/10.1128/AAC.02304-15.